Circulating nociceptin levels during the cluster headache period

C. Ertsey, M. Hantos, G. Bozsik, K. Tekes

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The trigeminal innervation of the dura and its vessels has a prominent role in the mechanism of cluster headache. Nociceptin, an opioid neuropeptide, is the endogenous ligand of the OP-4 receptor, with both algesic and analgesic properties depending on the site of action. Nociceptin and its receptor are expressed by trigeminal ganglion cells where they co-localize with calcitonin gene-related peptide, a marker peptide of the trigeminovascular neurones. Nociceptin inhibits neurogenic dural vasodilatation, a phenomenon related to trigeminovascular activation. To explore its possible involvement in cluster headache, we studied circulating levels of nociceptin when attack-free during the cluster period, and also after the termination of the cluster period, using radioimmunoassay. In 14 cluster headache patients nociceptin levels during the cluster period were significantly lower than in age-, and sex-matched controls (4.91 ± 1.96 vs. 9.58 ± 2.57 pg/ml, P <0.01). After the termination of the cluster period nociceptin levels (8.60 ± 1.47 pg/ml) were not statistically different from controls. Nociceptin levels did not correlate with age, length of disease or episode length. Lower nociceptin levels during the cluster period may result in a defective regulation of trigeminal activity that might not protect sufficiently against the attacks.

Original languageEnglish
Pages (from-to)280-283
Number of pages4
JournalCephalalgia
Volume24
Issue number4
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Cluster Headache
Trigeminal Ganglion
Calcitonin Gene-Related Peptide
nociceptin
Neuropeptides
Vasodilation
Opioid Analgesics
Radioimmunoassay
Analgesics
Ligands
Neurons
Peptides

Keywords

  • Cluster headache
  • Human
  • Nociceptin
  • OP-4 receptor
  • Trigeminovascular system

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Circulating nociceptin levels during the cluster headache period. / Ertsey, C.; Hantos, M.; Bozsik, G.; Tekes, K.

In: Cephalalgia, Vol. 24, No. 4, 04.2004, p. 280-283.

Research output: Contribution to journalArticle

Ertsey, C. ; Hantos, M. ; Bozsik, G. ; Tekes, K. / Circulating nociceptin levels during the cluster headache period. In: Cephalalgia. 2004 ; Vol. 24, No. 4. pp. 280-283.
@article{88abe6e296e04b1dbae5419fbda3f7a4,
title = "Circulating nociceptin levels during the cluster headache period",
abstract = "The trigeminal innervation of the dura and its vessels has a prominent role in the mechanism of cluster headache. Nociceptin, an opioid neuropeptide, is the endogenous ligand of the OP-4 receptor, with both algesic and analgesic properties depending on the site of action. Nociceptin and its receptor are expressed by trigeminal ganglion cells where they co-localize with calcitonin gene-related peptide, a marker peptide of the trigeminovascular neurones. Nociceptin inhibits neurogenic dural vasodilatation, a phenomenon related to trigeminovascular activation. To explore its possible involvement in cluster headache, we studied circulating levels of nociceptin when attack-free during the cluster period, and also after the termination of the cluster period, using radioimmunoassay. In 14 cluster headache patients nociceptin levels during the cluster period were significantly lower than in age-, and sex-matched controls (4.91 ± 1.96 vs. 9.58 ± 2.57 pg/ml, P <0.01). After the termination of the cluster period nociceptin levels (8.60 ± 1.47 pg/ml) were not statistically different from controls. Nociceptin levels did not correlate with age, length of disease or episode length. Lower nociceptin levels during the cluster period may result in a defective regulation of trigeminal activity that might not protect sufficiently against the attacks.",
keywords = "Cluster headache, Human, Nociceptin, OP-4 receptor, Trigeminovascular system",
author = "C. Ertsey and M. Hantos and G. Bozsik and K. Tekes",
year = "2004",
month = "4",
doi = "10.1111/j.1468-2982.2004.00664.x",
language = "English",
volume = "24",
pages = "280--283",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Circulating nociceptin levels during the cluster headache period

AU - Ertsey, C.

AU - Hantos, M.

AU - Bozsik, G.

AU - Tekes, K.

PY - 2004/4

Y1 - 2004/4

N2 - The trigeminal innervation of the dura and its vessels has a prominent role in the mechanism of cluster headache. Nociceptin, an opioid neuropeptide, is the endogenous ligand of the OP-4 receptor, with both algesic and analgesic properties depending on the site of action. Nociceptin and its receptor are expressed by trigeminal ganglion cells where they co-localize with calcitonin gene-related peptide, a marker peptide of the trigeminovascular neurones. Nociceptin inhibits neurogenic dural vasodilatation, a phenomenon related to trigeminovascular activation. To explore its possible involvement in cluster headache, we studied circulating levels of nociceptin when attack-free during the cluster period, and also after the termination of the cluster period, using radioimmunoassay. In 14 cluster headache patients nociceptin levels during the cluster period were significantly lower than in age-, and sex-matched controls (4.91 ± 1.96 vs. 9.58 ± 2.57 pg/ml, P <0.01). After the termination of the cluster period nociceptin levels (8.60 ± 1.47 pg/ml) were not statistically different from controls. Nociceptin levels did not correlate with age, length of disease or episode length. Lower nociceptin levels during the cluster period may result in a defective regulation of trigeminal activity that might not protect sufficiently against the attacks.

AB - The trigeminal innervation of the dura and its vessels has a prominent role in the mechanism of cluster headache. Nociceptin, an opioid neuropeptide, is the endogenous ligand of the OP-4 receptor, with both algesic and analgesic properties depending on the site of action. Nociceptin and its receptor are expressed by trigeminal ganglion cells where they co-localize with calcitonin gene-related peptide, a marker peptide of the trigeminovascular neurones. Nociceptin inhibits neurogenic dural vasodilatation, a phenomenon related to trigeminovascular activation. To explore its possible involvement in cluster headache, we studied circulating levels of nociceptin when attack-free during the cluster period, and also after the termination of the cluster period, using radioimmunoassay. In 14 cluster headache patients nociceptin levels during the cluster period were significantly lower than in age-, and sex-matched controls (4.91 ± 1.96 vs. 9.58 ± 2.57 pg/ml, P <0.01). After the termination of the cluster period nociceptin levels (8.60 ± 1.47 pg/ml) were not statistically different from controls. Nociceptin levels did not correlate with age, length of disease or episode length. Lower nociceptin levels during the cluster period may result in a defective regulation of trigeminal activity that might not protect sufficiently against the attacks.

KW - Cluster headache

KW - Human

KW - Nociceptin

KW - OP-4 receptor

KW - Trigeminovascular system

UR - http://www.scopus.com/inward/record.url?scp=1842559848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842559848&partnerID=8YFLogxK

U2 - 10.1111/j.1468-2982.2004.00664.x

DO - 10.1111/j.1468-2982.2004.00664.x

M3 - Article

VL - 24

SP - 280

EP - 283

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 4

ER -